Last reviewed · How we verify
Beersheva Mental Health Center — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| testosterone gel (Androgel) | testosterone gel (Androgel) | marketed | Androgen replacement therapy | Androgen receptor | Endocrinology | |
| Amisulpride, Moclobemide | Amisulpride, Moclobemide | phase 3 | Atypical antipsychotic + Reversible MAOI | Dopamine D2/D3 receptors; Monoamine oxidase-A | Psychiatry | |
| Bexarotene (Targretin LGD1069) | Bexarotene (Targretin LGD1069) | phase 3 | Retinoid X receptor (RXR) agonist | RXR (Retinoid X Receptor) | Oncology |
Therapeutic area mix
- Endocrinology · 1
- Oncology · 1
- Psychiatry · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Acerus Pharmaceuticals Corporation · 1 shared drug class
- Acrux DDS Pty Ltd · 1 shared drug class
- Allergan · 1 shared drug class
- Alliance for Clinical Trials in Oncology · 1 shared drug class
- Bayer · 1 shared drug class
- Clarus Therapeutics, Inc. · 1 shared drug class
- Galderma R&D · 1 shared drug class
- Abbott · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Beersheva Mental Health Center:
- Beersheva Mental Health Center pipeline updates — RSS
- Beersheva Mental Health Center pipeline updates — Atom
- Beersheva Mental Health Center pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Beersheva Mental Health Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/beersheva-mental-health-center. Accessed 2026-05-18.